Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2025 / Jan / Transforming Tumor Testing
Clinical Omics Genomics & DNA Analysis News and Research

Transforming Tumor Testing

Ribosomal RNA modifications as biomarkers provide insights into epitranscriptomic fingerprinting

By Jessica Allerton 01/08/2025 1 min read

Share

Original Image: Adobestock.com

A recent study published in Molecular Cell highlights the potential of ribosomal RNA (rRNA) modifications as powerful diagnostic tools. The researchers demonstrated that epitranscriptomic fingerprinting – a method based on analyzing rRNA modification patterns – can accurately identify tissue origins and distinguish tumors from normal samples. Using direct RNA sequencing (DRS), they discovered dynamic rRNA modification patterns across tissues, developmental stages, and cancer states.

DRS technology enables direct sequencing of native RNA molecules while preserving modification and sequence integrity. Using this technique, the researchers were able to classify tumor and normal samples with high accuracy using only 250 sequencing reads per sample. They also uncovered novel rRNA modification sites, including previously unannotated pseudouridylation residues, and mapped cancer-specific patterns. In lung cancer samples, differentially modified sites provided clear separation between tumor and normal tissues.

By analyzing over 220 rRNA modifications, including ribose methylation and pseudouridylation, the team demonstrated how these signatures are enriched in tumors and vary across tissue types. Machine learning further enhanced the predictive power of these modifications for diagnosing malignancies and determining tissue origins.

This method offers a significant advantage over traditional diagnostics. Unlike mRNA-focused techniques, which may lack stability or specificity, rRNA modifications provide distinct, robust signatures for classification. The approach requires minimal sampling, making it highly feasible for clinical applications. Beyond cancer, this method holds promise for identifying tissue-specific changes linked to normal development and disease progression.

Epitranscriptomic fingerprinting represents a major shift in diagnostics, the study reports. Its ability to leverage rRNA modifications for precise, non-invasive cancer detection and tissue identification paves the way for new diagnostic and therapeutic strategies. Future research could expand this method to other diseases and advance its use in clinical practice.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Associate Editor, The Analytical Scientist

More Articles by Jessica Allerton

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.